1989-53-3

Usage

Uses

Used in Pharmaceutical Industry:
2,6-Dimethoxybenzoyl chloride is used as an intermediate in the synthesis of various pharmaceutical compounds. Its chemical properties allow it to be a key component in the preparation of drugs with specific therapeutic applications.
Used in Chemical Synthesis:
2,6-Dimethoxybenzoyl chloride is used as a reagent in the chemical synthesis of various organic compounds. Its unique structure facilitates specific reactions that are crucial in the production of target molecules.
Used in Research and Development:
In the field of research and development, 2,6-Dimethoxybenzoyl chloride is utilized for the synthesis of novel compounds with potential applications in various industries. Its versatility in chemical reactions makes it a valuable tool for scientists and researchers.
Specific Applications:
2,6-Dimethoxybenzoyl chloride has been specifically used in the preparation of the following compounds:
1. 2,6-dimethoxyphenylpenicillindidechloro 2,6-Dimethoxybenzoyl chloride may have potential applications in the pharmaceutical industry, possibly as an antibiotic or related therapeutic agent.
2. OO-dimethylpyoluteorin This molecule could be used in the development of new dyes, pigments, or other chemical products with specific properties.

InChI:InChI=1/C9H9ClO3/c1-12-6-4-3-5-7(13-2)8(6)9(10)11/h3-5H,1-2H3

Upstream product

• 1466-76-8 2-6-dimethoxybenzoic acid 
• 707-74-4 (trichloromethyl)mesitylene 
• 7719-09-7 thionyl chloride 

Downstream Products

• 69819-00-7 2,6-dimethoxy-N-(5-nitro-thiazol-2-yl)-benzamide 
• 51483-25-1 6α-(2,6-dimethoxy-benzoyloxy)-penicillanic acid benzyl ester 
• 41324-27-0 2,6-dimethoxy-N-(7-oxa-3-thia-1-aza-spiro[5.5]undec-1-en-2-yl)-benzamide 
• 1797-80-4 2.6-Dimethoxybenzoesaeure-(p-nitrophenylester) 
• 53083-15-1 2,6-Dimethoxy-benzoic acid 3-oxo-2-(2,4,6-trimethyl-phenyl)-3H-inden-1-yl ester 
• 69017-43-2 2,6-Dimethoxy-benzoic acid 2-(2,6-dichloro-phenyl)-3-oxo-3H-inden-1-yl ester 
• 60576-96-7 2,6-Dimethoxy-benzoic acid 2-dimethylamino-2-phenyl-ethyl ester 
• 31709-80-5 2,6-dimethoxybenzoyl cyanide 
• 51579-20-5 methyl N-(2,6-dimethoxybenzoyl)glycine ester 
• 6684-04-4 2.6-Dimethoxy-monothiobenzoesaeure-S-aethylester 
• 69421-92-7 N-{3-[(4-Chloro-phenyl)-methyl-amino]-2-hydroxy-propyl}-2,6-dimethoxy-benzamide 
• 30154-81-5 O-[6β-(2,6-dimethoxy-benzoylamino)-penicillanoyl]-N-furfurylidene-hydroxylamine 
• 60576-85-4 2,6-Dimethoxy-benzoic acid 2-dimethylamino-2-phenyl-butyl ester 
• 29787-01-7 2',6'-dimethoxy-2,4,6-trimethyl-benzophenone 

Relevant academic research and scientific papers

Three xanthones from Poeciloneuron pauciflorum and Mammea acuminata

From the stem of Poeciloneuron pauciflorum, two new xanthones (1,6- dihydroxy-7-methoxyxanthone and 1,6-dihydroxy-7-methoxyxanthone 6-O-β-D- glucoside) in addition to 12 known compounds (1,5-dihydroxy-, 1,5-dihydroxy- 3-methoxy-, 1,7-dihydroxy-, 1-hydroxy-7-methoxy-, 2-methoxy-, 4-methoxy-, 1,4,5-trihydroxy-, 1,3,5-trihydroxy-, 1,3,6-trihydroxy-7-methoxy-, 1,3,7- trihydroxy-, 3-hydroxy-2-methoxyxanthone and (-)-epicatechin) were isolated. From the aerial paris (stems and bark) of Mammea acuminata, a new xanthone (2,7-dihydroxyxanthone) was isolated in addition to two known xanthones (1,5- dihydroxy- and 5-hydroxy-1-methoxyxanthone) and (-)-epicatechin. The structures were established by spectral analysis and total synthesis in case of 1,6-dihydroxy-7-methoxyxanthone.

Two xanthones from roots of Cratoxylum formosanum

From the roots of Cratoxylum formosanum, two new xanthones, 2,7- dihydroxy-1,8-dimethoxyxanthone and 1,4,7-trihydroxy-8-methoxyxanthone, were isolated, in addition to seven known xanthones and two flavonoids. Among the xanthones, 1,4,7-trihydroxyxanthone was the first isolation from the natural sources. Structures were determined by spectral analyses.

TRPV3 small molecule allosteric inhibitor and preparation method thereof

The present invention discloses a TRPV3 small molecule allosteric inhibitor and a preparation method thereof. The small molecule inhibitor comprises compounds represented by a general formula (I) anda general formula (II) shown in the specification or pharmaceutically acceptable salts thereof, wherein X is selected from N or C, Y is selected from (CH2) or (CO); R2 is selected from hydrogen and halogen; R4 is selected from C1-C8 alkyl groups, C3-C8 cycloalkyl groups, a naphthalene ring, an adamantyl group, morpholine, 4-(methylsulfonyl) piperazine and 4-(trifluoromethyl)pyridine-2-amine; and R1 and R3 are respectively and independently selected from hydrogen, deuterium, halogen, hydroxyl, sulfydryl, cyano, nitro, C1-C8 alkyl, halogenated C1-C8 alkyl, C1-C8 alkoxy, C3-C8 naphthenic bases, C3-C8 cycloalkenyl, C2-C8 alkenyl, C2-C8 alkynyl, C6-C10 aryl, C3-C10 heteroaryl and C4-C8 heterocyclic radical.

Computational discovery, structural optimization and biological evaluation of novel inhibitors targeting transient receptor potential vanilloid type 3 (TRPV3)

Transient receptor potential vanilloid type 3 (TRPV3) is a Ca2+ permeable nonselective cation channel and expressed abundantly in skin keratinocytes. TRPV3 emerges as an attractive target for treatment of pruritic, inflammatory, pain and skin-related diseases. However, only a few reports of TRPV3 inhibitors exist at present besides some patents. Therefore, TRPV3 research has always been fraught with challenges. Through a combination of virtual screening and biological evaluation, compound P1 (10 μM) was identified as a top hit with 34.5% inhibitory effect on 2-APB (1 mM)-evoked currents of mTRPV3-WT. Further structural optimization provided the inhibitor PC5 with the best activity (IC50 = 2.63 ± 0.28 μM), and point mutation assays indicated that amino acids V629 and F633 are crucial for the binding of PC5 and TRPV3. In summary, these newly discovered inhibitors could serve as promising lead compounds for the development of TRPV3 inhibitors in the future.

Synthesis of 3-aryl-1-phosphinoimidazo[1,5-a]pyridine ligands for use in Suzuki-Miyaura cross-coupling reactions

3-Aryl-1-phosphinoimidazo[1,5-a]pyridine ligands were synthesized from 2-aminomethylpyridine as the initial substrateviatwo complementary routes. The first synthetic pathway underwent the coupling of 2-aminomethylpyridine with substituted benzoyl chlorides, followed by cyclization, iodination and palladium-catalyzed cross-coupling phosphination reactions sequence to give our phosphorus ligands. In the second route, 2-aminomethylpyridine was cyclized with aryl aldehydes, followed by the iodination and palladium-catalyzed cross-coupling phosphination reactions to yield our phosphorus ligands. The 3-aryl-1-phosphinoimidazo[1,5-a]pyridine ligands were evaluated in palladium-catalyzed sterically-hindered biaryl and heterobiaryl Suzuki-Miyaura cross-coupling reactions.

Late-Stage β-C(sp3)-H Deuteration of Carboxylic Acids

Carboxylic acids are highly abundant in bioactive molecules. In this study, we describe the late-stage β-C(sp3)-H deuteration of free carboxylic acids. On the basis of the finding that C-H activation with our catalysts is reversible, the de-deuteration process was first optimized. The resulting method uses ethylenediamine-based ligands and can be used to achieve the desired deuteration when using a deuterated solvent. The reported method allows for the functionalization of a wide range of free carboxylic acids with diverse substitution patterns, as well as the late-stage deuteration of bioactive molecules and related frameworks and enables the functionalization of nonactivated methylene β-C(sp3)-H bonds for the first time.

6,7-Dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline amides and corresponding ester isosteres as multidrug resistance reversers

Aiming to deepen the structure–activity relationships of the two P-glycoprotein (P-gp) modulators elacridar and tariquidar, a new series of amide and ester derivatives carrying a 6,7-dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline scaffold linked to different methoxy-substituted aryl moieties were synthesised. The obtained compounds were evaluated for their P-gp interaction profile and selectivity towards the two other ABC transporters, multidrug-resistance-associated protein-1 and breast cancer resistance protein, showing to be very active and selective versus P-gp. Two amide derivatives, displaying the best P-gp activity, were tested in co-administration with the antineoplastic drug doxorubicin in different cancer cell lines, showing a significant sensitising activity towards doxorubicin. The investigation on the chemical stability of the derivatives towards spontaneous or enzymatic hydrolysis, showed that amides are stable in both models while some ester compounds were hydrolysed in human plasma. This study allowed us to identify two chemosensitizers that behave as non-transported substrates and are characterised by different selectivity profiles.

Preparation method of 2,4,6-trimethylbenzoyl chloride and acyl chloride co-production technology

The invention relates to the field of new materials of fine chemicals, in particular to 2,4,6-trimethylbenzoyl chloride (also known as trimesoyl chloride) and an environment-friendly and economical novel preparation process technology for co-producing series acyl chloride products.

Preparation method of 2,6-dimethoxybenzoyl chloride

The invention discloses a preparation method of 2,6-dimethoxybenzoyl chloride and belongs to the technical field of medicine techniques. The technical problem to be solved by the invention is to relate to a more advanced preparation method of 2,6-dimethoxybenzoyl chloride. The main point of the technical scheme for solving the technical problem by the invention is a new preparation method of the compound.

Electrochemical C-H cyanation of electron-rich (Hetero)arenes

A straightforward method for the electrochemical C-H cyanation of arenes and heteroarenes that proceeds at room temperature in MeOH, with NaCN as the reagent in a simple, open, undivided electrochemical cell is reported. The platinum electrodes are passivated by ad-sorbed cyanide, which allows conversion of an exceptionally broad range of electron-rich substrates all the way down to dialkyl arenes. The cyanide electrolyte can be replenished with HCN, opening opportunities for salt-free industrial C-H cyanation.